Cipher Pharmaceuticals Gross Profit vs. Current Valuation
| CPH Stock | CAD 14.87 0.05 0.34% |
Gross Profit | First Reported 2004-03-31 | Previous Quarter 4.2 M | Current Value 8.4 M | Quarterly Volatility 3 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.95 | 0.8077 |
|
|
For Cipher Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cipher Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cipher Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cipher Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cipher Pharmaceuticals over time as well as its relative position and ranking within its peers.
Cipher |
Cipher Pharmaceuticals Current Valuation vs. Gross Profit Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Cipher Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Cipher Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Cipher Pharmaceuticals is rated second in gross profit category among its peers. It is the top company in current valuation category among its peers reporting about 25.46 of Current Valuation per Gross Profit. At this time, Cipher Pharmaceuticals' Gross Profit is very stable compared to the past year. Comparative valuation analysis is a catch-all model that can be used if you cannot value Cipher Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cipher Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Cipher Current Valuation vs. Gross Profit
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Cipher Pharmaceuticals |
| = | 16.68 M |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Cipher Pharmaceuticals |
| = | 424.78 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Cipher Current Valuation vs Competition
Cipher Pharmaceuticals is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 549.3 Million. Cipher Pharmaceuticals totals roughly 424.78 Million in current valuation claiming about 77% of equities under Health Care industry.
Cipher Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Cipher Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cipher Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Cipher Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Cipher Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -8.6 M | -8.1 M | |
| Operating Income | 11.5 M | 12.1 M | |
| Income Before Tax | 12.7 M | 13.3 M | |
| Total Other Income Expense Net | 1.2 M | 1.2 M | |
| Net Income | 20.4 M | 21.4 M | |
| Income Tax Expense | -7.7 M | -7.3 M | |
| Net Income From Continuing Ops | 20.4 M | 21.4 M | |
| Net Income Applicable To Common Shares | 30.6 M | 32.2 M | |
| Interest Income | 1.9 M | 1.5 M | |
| Net Interest Income | 1.9 M | 2 M | |
| Change To Netincome | -12.6 M | -12 M | |
| Net Income Per Share | 0.80 | 0.84 | |
| Income Quality | 0.78 | 0.75 | |
| Net Income Per E B T | 1.61 | 1.69 |
Cipher Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Cipher Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cipher Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cipher Pharmaceuticals' important profitability drivers and their relationship over time.
Use Cipher Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cipher Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cipher Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Cipher Pharmaceuticals Pair Trading
Cipher Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Cipher Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cipher Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cipher Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cipher Pharmaceuticals to buy it.
The correlation of Cipher Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cipher Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cipher Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cipher Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Cipher Pharmaceuticals position
In addition to having Cipher Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Precious Metals Thematic Idea Now
Precious Metals
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Precious Metals theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Precious Metals Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Cipher Stock
To fully project Cipher Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Cipher Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Cipher Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.